In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (10/2007)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Cardiovascular Drug Start-Ups," features profiles of AcelleRX Therapeutics, BioVascular, Nile Therapeutics and VIA Pharmaceuticals. Plus these Start-Ups Across Health Care: JenaValve, Moberg Derma, ProtAffin, and Virtual Ports.

You may also be interested in...



Moberg Derma AB

Swedish dermatology specialty pharma Moberg Derma AB is using its Kaprolac platform to build a portfolio of non-steroidal, topical treatments that it thinks will have improved therapeutic outcomes and mitigated side-effect profiles. Kaprolac is a combination of several well-known, safe dermatological compounds that have given rise to a potential 10 new treatments in Moberg Derma's pipeline.

Via Pharmaceuticals Inc.

There's a lot of excitement around the new insights that vulnerable plaque, a certain kind of inflammatory plaque, is the culprit in myocardial infarction, but so far, no one has figured out how to treat it. Thomas Quertermous of Stanford has identified inflammatory pathways that contribute to atherosclerosis and Via Pharmaceuticals was formed to develop a drug, already tested extensively in humans, that emanated from his research program.

AcelleRX Therapeutics Inc.

AcelleRX Therapeutics aims to help people who suffer a myocardial infarction (MI) or chronic heart failure (HF) via a gene or protein capable of recruiting stem cells to help repair the heart. If the science can be successfully commercialized, this spin-out from the Cleveland Clinic in Ohio could have a big impact on a big slice of the market.

Related Content

Related Companies

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel